The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study

Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Jan 11, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring the effects of a medication called GLP-1 analog on patients with hypothalamic obesity, which can occur after surgery for hypothalamic tumors. The researchers want to see if this medication can help these patients lose weight and if different types of hypothalamic obesity respond differently to the treatment. This study is still recruiting participants, and they are looking for adults aged 19 and older who have a body mass index (BMI) of 27 or higher and have had surgery for a hypothalamic tumor that caused damage.

If you or a family member are interested in participating, you would need to be able to understand the study instructions and give consent. Participants will take the GLP-1 medication and be monitored throughout the trial. This research is important because it could help us understand better ways to treat obesity linked to hypothalamic issues, and it might provide insights into how specific brain areas contribute to this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with a hypothalamic tumor and treated surgically with confirmed hypothalamic damage
• • 19 years of age or older
• • Have a body mass index of at least 27 and less than 30 (27≤BMI\<30) and one or more confirmed weight-related medical conditions, or a body mass index of 30 or greater (BMI≥30).
• • Voluntarily agreed to participate in the study after receiving a full explanation of the study.
• Exclusion Criteria:
• • Unable to fully understand the instructions for participation in the study or unable to give voluntary consent.
• • Presence or history of a medical condition or disease that, in the opinion of the investigator, would make it difficult for the patient to participate fully for the duration of the study or to interpret the results of the study
• • Taking medications that may affect weight, except for hormone replacement therapy, in the last 6 months
• • non-primary tumor patient
• • Diagnosis of severe renal dysfunction, liver dysfunction, or thyroid disease among other underlying conditions